Overview

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2024-02-29

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Blueprint Medicines Corporation
Hoffmann-La Roche

Treatments:

Pralsetinib